{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:59:21Z","timestamp":1783400361124,"version":"3.54.6"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.euroneuro.2005.01.006","type":"journal-article","created":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T13:30:03Z","timestamp":1111671003000},"page":"505-509","source":"Crossref","is-referenced-by-count":20,"title":["Hydrosoluble fiber (Plantago ovata husk) and levodopa II: Experimental study of the pharmacokinetic interaction in the presence of carbidopa"],"prefix":"10.1016","volume":"15","author":[{"given":"Nelida","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrio","family":"Carriedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Jose","family":"Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sahagun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2005.01.006_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(02)09733-7","article-title":"Levodopa: why the controversy?","volume":"360","author":"Agid","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2005.01.006_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.0954-6820.1975.tb19565.x","article-title":"Intestinal decarboxylation of orally administered l-dopa: influence of pharmacological preparations, dose magnitude, dose sequence and food intake","volume":"198","author":"Anderson","year":"1975","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1023\/A:1018970617104","article-title":"Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration","volume":"11","author":"Bredberg","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF00315415","article-title":"Pharmacokinetics and effects of levodopa in advanced Parkinson's disease","volume":"39","author":"Bredberg","year":"1990","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib5","first-page":"S15","article-title":"Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson\u00b4s disease","volume":"44","author":"Chase","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2005.01.006_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00002826-199002000-00002","article-title":"Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations","volume":"13","author":"Contin","year":"1990","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1212\/WNL.43.2.367","article-title":"Pharmacodynamic modelling of oral levodopa: clinical application in Parkinson's disease","volume":"43","author":"Contin","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2005.01.006_bib8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/BF00170645","article-title":"In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle: a microdialysis study","volume":"344","author":"Deleu","year":"1991","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/mds.870100113","article-title":"Effect of cisapride on response fluctuations in Parkinson's disease","volume":"10","author":"Djaldetti","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib10","first-page":"168","article-title":"Improvement of the oral absorption of levodopa in the presence of psyllium","volume":"25","author":"Fern\u00e1ndez","year":"2003","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib11","first-page":"10","article-title":"Gastrointestinal dysmotility and central nervous system disorders: use of cisapride in patients with Parkinson's disease","volume":"11","author":"Garnett","year":"1996","journal-title":"Consult. Pharm."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib12","series-title":"Multicompartment models, Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.euroneuro.2005.01.006_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000116858","article-title":"Comparative multiple-dose pharmacokinetics of controlled-release levodopa products","volume":"3","author":"Grahnen","year":"1992","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1023\/A:1010935228654","article-title":"A pharmacokinetic model to predict the PK interaction of l-dopa and benserazide in rats","volume":"18","author":"Grange","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF02801866","article-title":"Effect of dietary fiber on proteolytic pancreatic enzymes in vitro","volume":"1","author":"Hansen","year":"1986","journal-title":"Int. J. Pancreatol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.2042-7158.1979.tb13479.x","article-title":"The effect of simultaneous administration of 3,4-dihydroxyphenylpyruvic acid and l-dopa on the bioavailability of l-dopa in rat and mouse","volume":"31","author":"Hietala","year":"1979","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib17","first-page":"195","article-title":"A comparison of the effects of reversible and irreversible inhibitors of aromatic l-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral l-3,4-dihydroxyphenylalanine","volume":"11","author":"Huebert","year":"1986","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib18","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(82)80256-4","article-title":"Effect of dietary fiber on pancreatic enzyme activity in vitro","volume":"82","author":"Isaksson","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.euroneuro.2005.01.006_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1079\/BJN19910035","article-title":"Plantago ovata seeds as dietary fibre supplement, physiological and metabolic effects in rats","volume":"66","author":"Leng-Peschlow","year":"1991","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1023\/A:1015946114321","article-title":"The effects of carbidopa dose and time and route of administration on systemic l-dopa levels in rats","volume":"5","author":"Leppert","year":"1988","journal-title":"Pharm. Res."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.2042-7158.1980.tb12933.x","article-title":"Effects of 3,4-dihydroxyphenylpyruvic acid and l-glutamic acid on some pharmacokinetic parameters of l-dopa in the rat","volume":"32","author":"Linden","year":"1980","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.410270105","article-title":"Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson\u00b4s disease","volume":"27","author":"Mouradian","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00002826-198904000-00002","article-title":"Pharmacokinetic and pharmacodynamic modeling of l-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet","volume":"12","author":"Nelson","year":"1989","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.40.2.340","article-title":"Levodopa-induced dyskinesia: review, observations, and speculations","volume":"40","author":"Nutt","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2005.01.006_bib25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJM198402233100802","article-title":"The \u201con\u2013off\u201d phenomenon in Parkinson's disease: relation to levodopa absorption and transport","volume":"310","author":"Nutt","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002826-198403000-00002","article-title":"Pharmacokinetics of levodopa","volume":"7","author":"Nutt","year":"1984","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00002826-200203000-00006","article-title":"Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations","volume":"25","author":"Nyholm","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib28","first-page":"15","article-title":"l-dopa: how it may exacerbate Parkinsonian symptoms","volume":"9","author":"Paalzow","year":"1986","journal-title":"TIPS"},{"key":"10.1016\/j.euroneuro.2005.01.006_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003495-197611050-00001","article-title":"Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of Parkinsonism","volume":"11","author":"Pinder","year":"1976","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2005.01.006_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/bmj.4.5727.93","article-title":"l-dopa treatment failure: explanation and correction","volume":"10","author":"Rivera-Calimlim","year":"1970","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2005.01.006_bib31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ana.410290609","article-title":"Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced chorea","volume":"29","author":"Sage","year":"1991","journal-title":"Ann. Neurol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X05000374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X05000374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T06:45:04Z","timestamp":1706078704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X05000374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0924977X05000374"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2005.01.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}